Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
Details : Ono and PRISM will jointly develop a candidate for Ono’s oncology target using PepMetics, small molecules that mimic 3D structures of alpha-helix and beta-turn peptides for drug discovery.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : $660.0 million
Deal Type : Collaboration
Details : Under the collaboration, PRISM and Lilly will work together to discover oral, small molecule inhibitors of a protein-protein interaction (PPI) target selected by Lilly utilizing PRISM's proprietary PepMetics® technology.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : $660.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
